V Craig Jordan

List of Publications by Year
in descending order

186	15,250	31976 53	17592 121
papers	citations	h-index	g-index

189	189	189	9916
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	PERK, Beyond an Unfolded Protein Response Sensor in Estrogen-Induced Apoptosis in Endocrine-Resistant Breast Cancer. Molecular Cancer Research, 2022, 20, 193-201.	3.4	13
2	â€œIf I wanted to buy your brain, what would that cost?â€: rebirth at M.D. Anderson Cancer Center. , 2022, , 187-194.		0
3	An account of students obtaining a Ph.D. degree (or an MD for physicians in the British System) while inÂthe Tamoxifen Team over the last 50 years. , 2022, , 207-220.		0
4	Get out and go to Georgetown. , 2022, , 163-169.		0
5	Closing the circle on Tamoxifen Tales. , 2022, , 171-186.		0
6	Estrogen Receptor Complex to Trigger or Delay Estrogen-Induced Apoptosis in Long-Term Estrogen Deprived Breast Cancer. Frontiers in Endocrinology, 2022, 13, 869562.	3.5	3
7	Estrogen Receptor and the Unfolded Protein Response: Double-Edged Swords in Therapy for Estrogen Receptor-Positive Breast Cancer. Targeted Oncology, 2022, 17, 111-124.	3.6	7
8	Estrogen for the Treatment and Prevention of Breast Cancer. Cancer Journal (Sudbury, Mass), 2022, 28, 163-168.	2.0	2
9	Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer. Molecular Cancer Therapeutics, 2021, 20, 11-25.	4.1	11
10	50th anniversary of the first clinical trial with ICI 46,474 (tamoxifen): then what happened?. Endocrine-Related Cancer, 2021, 28, R11-R30.	3.1	25
11	Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team. Breast Cancer Research and Treatment, 2021, 190, 19-38.	2.5	6
12	Molecular Mechanism for Breast Cancer Incidence in the Women's Health Initiative. Cancer Prevention Research, 2020, 13, 807-816.	1.5	17
13	Pharmacology and Molecular Mechanisms of Clinically Relevant Estrogen Estetrol and Estrogen Mimic BMI-135 for the Treatment of Endocrine-Resistant Breast Cancer. Molecular Pharmacology, 2020, 98, 364-381.	2.3	17
14	The Structure-Function Relationship of Angular Estrogens and Estrogen Receptor Alpha to Initiate Estrogen-Induced Apoptosis in Breast Cancer Cells. Molecular Pharmacology, 2020, 98, 24-37.	2.3	19
15	Serendipity in the search for â€œmorning-after pillsâ€•led to clomiphene for the induction of ovulation. F&S Science, 2020, 1, 3-13.	0.9	0
16	Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERÎ±-positive breast cancer. Exploration of Targeted Anti-tumor Therapy, 2020, 1, 355-371.	0.8	4
17	ASO Author Reflections: An Optimal Biological Model for Successful Drug Discovery. Annals of Surgical Oncology, 2019, 26, 1991-1992.	1.5	0
18	Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM. Journal of Clinical Oncology, 2019, 37, 1982-1983.	1.6	17

#	Article	IF	Citations
19	The SERM Saga, Something from Nothing: American Cancer Society/SSO Basic Science Lecture. Annals of Surgical Oncology, 2019, 26, 1981-1990.	1.5	11
20	Suppression of Nuclear Factor-ÎºB by Glucocorticoid Receptor Blocks Estrogen-Induced Apoptosis in Estrogen-Deprived Breast Cancer Cells. Molecular Cancer Therapeutics, 2019, 18, 1684-1695.	4.1	19
21	A life in breast cancer research: tamoxifen, SERMs and the unique paired-biology of the unfolded protein response and apoptosis. Breast Cancer Management, 2019, 8, BMT21.	0.2	1
22	The First Targeted Therapy to Treat Cancer: The Tamoxifen Tale. Cancer Drug Discovery and Development, 2019, , 151-188.	0.4	1
23	Estrogen-Induced Apoptosis in Breast Cancers Is Phenocopied by Blocking Dephosphorylation of Eukaryotic Initiation Factor 2 Alpha (eIF2Î±) Protein. Molecular Cancer Research, 2019, 17, 918-928.	3.4	15
24	A Novel Strategy to Improve Womenâ€™s Health: Selective Estrogen Receptor Modulators. Cancer Drug Discovery and Development, 2019, , 189-213.	0.4	5
25	New insights into acquired endocrine resistance of breast cancer. , 2019, 2, 198-209.		32
26	The Study of Letrozole Extension (SOLE) revisited. Lancet Oncology, The, 2018, 19, e77.	10.7	3
27	Tamoxifen Resistance Trumped and Oral Selective Estrogen Receptor Degraders Arrive. Clinical Cancer Research, 2018, 24, 3480-3482.	7.0	8
28	Modulation of nuclear factor-kappa B activation by the endoplasmic reticulum stress sensor PERK to mediate estrogen-induced apoptosis in breast cancer cells. Cell Death Discovery, 2018, 4, 15.	4.7	52
29	Steroid Receptors in Breast Cancer. , 2018, , 272-281.e2.		2
30	A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers. Endocrine-Related Cancer, 2018, 25, R83-R113.	3.1	21
31	Rethinking Extended Adjuvant Antiestrogen Therapy to Increase Survivorship in Breast Cancer. JAMA Oncology, 2018, 4, 15.	7.1	24
32	How PERK kinase conveys stress signals to nuclear factor-ÎºB to mediate estrogen-induced apoptosis in breast cancer cells?. Cell Death and Disease, 2018, 9, 842.	6.3	11
33	Moving Precision Oncology Forward Amid Myths and Misconceptions. JAMA Oncology, 2018, 4, 1789.	7.1	2
34	Targeting Peroxisome Proliferator-Activated Receptor Î³ to Increase Estrogen-Induced Apoptosis in Estrogen-Deprived Breast Cancer Cells. Molecular Cancer Therapeutics, 2018, 17, 2732-2745.	4.1	22
35	Successful Targeted Therapies for Breast Cancer: the Worcester Foundation and Future Opportunities in Womenâ€™s Health. Endocrinology, 2018, 159, 2980-2990.	2.8	17
36	Endoxifen, 4-Hydroxytamoxifen and an Estrogenic Derivative Modulate Estrogen Receptor Complex Mediated Apoptosis in Breast Cancer. Molecular Pharmacology, 2018, 94, 812-822.	2.3	24

#	Article	IF	Citations
37	Opportunities and challenges of long term anti-estrogenic adjuvant therapy: treatment forever or intermittently?. Expert Review of Anticancer Therapy, 2017, 17, 297-310.	2.4	3
38	Tamoxifen Decreases Mortality, but How?. Journal of Clinical Oncology, 2017, 35, 379-379.	1.6	1
39	The 4Ps of Breast Cancer Chemoprevention: Putting Proven Principles into Practice. Cancer Prevention Research, 2017, 10, 219-222.	1.5	2
40	Concerns About Methodology of a Trial Investigating Vaginal Health During Aromatase Inhibitor Therapy for Breast Cancer. JAMA Oncology, 2017, 3, 1141.	7.1	2
41	Angela M. Hartley Brodie (1934â€“2017). Nature, 2017, 548, 32-32.	27.8	6
42	Long-term Adjuvant Tamoxifen Therapy and Decreases in Contralateral Breast Cancer. JAMA Oncology, 2017, 3, 163.	7.1	4
43	Endoxifen: The End, or Are We at the Beginning?. Journal of Clinical Oncology, 2017, 35, 3378-3379.	1.6	6
44	A Raloxifene Withdrawal Response. Integrative Cancer Therapies, 2016, 15, 242-244.	2.0	1
45	The modulation of estrogen-induced apoptosis as an interpretation of the womenâ€™s health initiative trials. Expert Review of Endocrinology and Metabolism, 2016, 11, 81-86.	2.4	10
46	Estrogen Deprivation Therapy in Ovarian Cancer: An Opportunity. Journal of Clinical Oncology, 2016, 34, 2675-2676.	1.6	0
47	A Retrospective: On Clinical Studies with 5-Fluorouracil. Cancer Research, 2016, 76, 767-768.	0.9	20
48	Differing Perspectives on Breast Cancer Chemoprevention. JAMA Oncology, 2016, 2, 276.	7.1	1
49	Profiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer. Oncotarget, 2016, 7, 71235-71254.	1.8	13
50	Is There a Role for Raloxifene and Tamoxifen for the Prevention of Breast Cancer?. , 2016, , 83-101.		0
51	Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer. Discovery Medicine, 2016, 21, 411-27.	0.5	16
52	Tamoxifen, raloxifene and selective estrogen receptor modulators to estrogen-induced apoptosis, one thing led to another. Breast Cancer Management, 2015, 4, 289-293.	0.2	0
53	Cancer chemoprevention at the crossroads?. Breast Cancer Management, 2015, 4, 285-288.	0.2	0
54	Oral pure antiestrogens as a solution to acquired drug resistance to aromatase inhibitors. Breast Cancer Management, 2015, 4, 275-277.	0.2	0

#	Article	IF	Citations
55	The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocrine-Related Cancer, 2015, 22, R1-R31.	3.1	111
56	Inhibition of BET proteins impairs estrogen-mediated growth and transcription in breast cancers by pausing RNA polymerase advancement. Breast Cancer Research and Treatment, 2015, 150, 265-278.	2.5	30
57	The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy. Molecular and Cellular Endocrinology, 2015, 418, 245-263.	3.2	27
58	Integration of Downstream Signals of Insulin-like Growth Factor-1 Receptor by Endoplasmic Reticulum Stress for Estrogen-Induced Growth or Apoptosis in Breast Cancer Cells. Molecular Cancer Research, 2015, 13, 1367-1376.	3.4	26
59	Proven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale. British Journal of Clinical Pharmacology, 2015, 79, 254-267.	2.4	11
60	Estrogen Receptor Mutations Found in Breast Cancer Metastases Integrated With the Molecular Pharmacology of Selective ER Modulators. Journal of the National Cancer Institute, 2015, 107, djv075.	6.3	35
61	Progesterone and Synthetic Progestin Controversies. JAMA Oncology, 2015, 1, 986.	7.1	1
62	Obesity and male breast cancer: provocative parallels?. BMC Medicine, 2015, 13, 134.	5.5	26
63	Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer.. Journal of Clinical Oncology, 2015, 33, 1500-1500.	1.6	5
64	Mechanisms underlying differential response to estrogen-induced apoptosis in long-term estrogen-deprived breast cancer cells. International Journal of Oncology, 2014, 44, 1529-1538.	3.3	31
65	Pharmacological Relevance of Endoxifen in a Laboratory Simulation of Breast Cancer in Postmenopausal Patients. Journal of the National Cancer Institute, 2014, 106, .	6.3	17
66	Molecular Modulation of Estrogen-Induced Apoptosis by Synthetic Progestins in Hormone Replacement Therapy: An Insight into the Women's Health Initiative Study. Cancer Research, 2014, 74, 7060-7068.	0.9	44
67	Linking Estrogen-Induced Apoptosis With Decreases in Mortality Following Long-term Adjuvant Tamoxifen Therapy. Journal of the National Cancer Institute, 2014, 106, dju296-dju296.	6.3	34
68	Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer. Endocrine-Related Cancer, 2014, 21, R235-R246.	3.1	128
69	Avoiding the Bad and Enhancing the Good of Soy Supplements in Breast Cancer. Journal of the National Cancer Institute, 2014, 106, dju233-dju233.	6.3	19
70	A(nother) scientific strategy to prevent breast cancer in postmenopausal women by enhancing estrogen-induced apoptosis?. Menopause, 2014, 21, 1160-1164.	2.0	10
71	Cyclin dependent kinase-9 mediated transcriptional de-regulation of cMYC as a critical determinant of endocrine-therapy resistance in breast cancers. Breast Cancer Research and Treatment, 2014, 143, 113-124.	2.5	42
72	Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells. European Journal of Cancer, 2014, 50, 457-468.	2.8	45

#	Article	IF	Citations
73	Novel Selective Estrogen Mimics for the Treatment of Tamoxifen-Resistant Breast Cancer. Molecular Cancer Therapeutics, 2014, 13, 2515-2526.	4.1	17
74	Introduction to a special edition in Steroids of nuclear hormone receptor modulators. Steroids, 2014, 90, 1-2.	1.8	2
75	Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different <scp>CYP2D</scp>6 genotypes. British Journal of Pharmacology, 2014, 171, 5624-5635.	5.4	29
76	The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators. Steroids, 2014, 90, 3-12.	1.8	22
77	Defining the Conformation of the Estrogen Receptor Complex That Controls Estrogen-Induced Apoptosis in Breast Cancer. Molecular Pharmacology, 2014, 85, 789-799.	2.3	24
78	Selective estrogen-induced apoptosis in breast cancer. Steroids, 2014, 90, 60-70.	1.8	11
79	A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer. European Journal of Cancer, 2014, 50, 2866-2876.	2.8	46
80	Influence of the Length and Positioning of the Antiestrogenic Side Chain of Endoxifen and 4-Hydroxytamoxifen on Gene Activation and Growth of Estrogen Receptor Positive Cancer Cells. Journal of Medicinal Chemistry, 2014, 57, 4569-4583.	6.4	18
81	Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations. Steroids, 2014, 90, 44-52.	1.8	30
82	Identification of gene regulation patterns underlying both oestrogen- and tamoxifen-stimulated cell growth through global gene expression profiling in breast cancer cells. European Journal of Cancer, 2014, 50, 2877-2886.	2.8	15
83	Breast Cancer Cell Apoptosis with Phytoestrogens Is Dependent on an Estrogen-Deprived State. Cancer Prevention Research, 2014, 7, 939-949.	1.5	48
84	Estrogen-Mediated Mechanisms to Control the Growth and Apoptosis of Breast Cancer Cells. Vitamins and Hormones, 2013, 93, 1-49.	1.7	13
85	c-Src Modulates Estrogen-Induced Stress and Apoptosis in Estrogen-Deprived Breast Cancer Cells. Cancer Research, 2013, 73, 4510-4520.	0.9	77
86	Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality. Menopause, 2013, 20, 372-382.	2.0	34
87	The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice. Current Clinical Pharmacology, 2013, 8, 135-155.	0.6	297
88	Estrogen Action, Selective Estrogen Receptor Modulators and Women's Health. , 2013, , .		6
89	Models and mechanisms of acquired antihormone resistance in breast cancer: significant clinical progress despite limitations. Hormone Molecular Biology and Clinical Investigation, 2012, 9, 143-163.	0.7	62
90	Adapting to change and seeing the opportunities in breast cancer management. Breast Cancer Management, 2012, 1, 1-3.	0.2	0

#	Article	IF	Citations
91	Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines. European Journal of Cancer, 2012, 48, 3488-3498.	2.8	37
92	Paradoxical Clinical Effect of Estrogen on Breast Cancer Risk: A â€œNewâ€•Biology of Estrogen-induced Apoptosis. Cancer Prevention Research, 2011, 4, 633-637.	1.5	59
93	Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18879-18886.	7.1	151
94	The Selective Estrogen Receptor Modulator Bazedoxifene Inhibits Hormone-Independent Breast Cancer Cell Growth and Down-Regulates Estrogen Receptor Î± and Cyclin D1. Molecular Pharmacology, 2011, 80, 610-620.	2.3	113
95	The conformation of the estrogen receptor directs estrogen-induced apoptosis in breast cancer: a hypothesis. Hormone Molecular Biology and Clinical Investigation, 2011, 5, 27-34.	0.7	17
96	Estrogen Activity in Plastic Products: Yang et al. Respond. Environmental Health Perspectives, 2011, 119, .	6.0	1
97	Proteomic Analysis of Pathways Involved in Estrogen-Induced Growth and Apoptosis of Breast Cancer Cells. PLoS ONE, 2011, 6, e20410.	2.5	28
98	Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: A unifying concept in anti-hormone resistance. International Journal of Oncology, 2010, 37, 387-98.	3.3	18
99	Estrogen regulation of X-box binding protein-1 and its role in estrogen induced growth of breast and endometrial cancer cells. Hormone Molecular Biology and Clinical Investigation, 2010, 2, 235-243.	0.7	58
100	Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer. Cancer Prevention Research, 2010, 3, 696-706.	1.5	560
101	Structureâ^'Function Relationships of Estrogenic Triphenylethylenes Related to Endoxifen and 4-Hydroxytamoxifen. Journal of Medicinal Chemistry, 2010, 53, 3273-3283.	6.4	40
102	Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: A potential clinical application of angiogenesis inhibitors. European Journal of Cancer, 2010, 46, 1537-1553.	2.8	40
103	Expression of estrogen receptor alpha with a Tet-off adenoviral system induces G0/G1 cell cycle arrest in SKBr3 breast cancer cells. International Journal of Oncology, 2010, 36, 451-8.	3.9	4
104	Potential of l-buthionine sulfoximine to enhance the apoptotic action of estradiol to reverse acquired antihormonal resistance in metastatic breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 2009, 114, 33-39.	2.5	19
105	Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?. Breast Cancer Research, 2009, 11, 206.	5.0	208
106	Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis. Breast Cancer Research, 2008, 10, R104.	5.0	58
107	Tamoxifen: Catalyst for the change to targeted therapy. European Journal of Cancer, 2008, 44, 30-38.	2.8	174
108	The 38th David A. Karnofsky Lecture: The Paradoxical Actions of Estrogen in Breast Cancerâ€"Survival or Death?. Journal of Clinical Oncology, 2008, 26, 3073-3082.	1.6	98

#	Article	IF	Citations
109	Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids, 2007, 72, 7-25.	1.8	282
110	Selective Estrogen-Receptor Modulators and Antihormonal Resistance in Breast Cancer. Journal of Clinical Oncology, 2007, 25, 5815-5824.	1.6	285
111	Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nature Reviews Cancer, 2007, 7, 46-53.	28.4	198
112	Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer. International Journal of Oncology, 2007, 30, 509-20.	3.3	18
113	Optimising endocrine approaches for the chemoprevention of breast cancer. European Journal of Cancer, 2006, 42, 2909-2913.	2.8	40
114	Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. British Journal of Pharmacology, 2006, 147, S269-S276.	5.4	254
115	Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes<SUBTITLE>The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2006, 295, 2727.	7.4	1,499
116	Development and Therapeutic Options for the Treatment of Raloxifene-Stimulated Breast Cancer in Athymic Mice. Clinical Cancer Research, 2006, 12, 2255-2263.	7.0	34
117	Improvements in tumor targeting, survivorship, and chemoprevention pioneered by tamoxifen. A personal perspective. Oncology, 2006, 20, 553-62; discussion 567-8, 573, 577.	0.5	4
118	Intrinsic Mechanism of Estradiol-Induced Apoptosis in Breast Cancer Cells Resistant to Estrogen Deprivation. Journal of the National Cancer Institute, 2005, 97, 1746-1759.	6.3	229
119	Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. Journal of Steroid Biochemistry and Molecular Biology, 2005, 93, 249-256.	2.5	48
120	Selective estrogen receptor modulation. Cancer Cell, 2004, 5, 207-213.	16.8	307
121	Tamoxifen: a most unlikely pioneering medicine. Nature Reviews Drug Discovery, 2003, 2, 205-213.	46.4	676
122	Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 2. Clinical Considerations and New Agents. Journal of Medicinal Chemistry, 2003, 46, 1081-1111.	6.4	392
123	Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 1. Receptor Interactions. Journal of Medicinal Chemistry, 2003, 46, 883-908.	6.4	396
124	Introducing a new section to Breast Cancer Research: Endocrinology and hormone therapy. Breast Cancer Research, 2003, 5, 281-3.	5.0	1
125	Paradoxical Action of Fulvestrant in Estradiol-Induced Regression of Tamoxifen-Stimulated Breast Cancer. Journal of the National Cancer Institute, 2003, 95, 1597-1608.	6.3	121
126	Modulation of Estrogen Receptor Î± Function and Stability by Tamoxifen and a Critical Amino Acid (Asp-538) in Helix 12. Journal of Biological Chemistry, 2003, 278, 7630-7638.	3.4	53

#	Article	IF	Citations
127	Apoptotic Action of 17Â-Estradiol in Raloxifene-Resistant MCF-7 Cells In Vitro and In Vivo. Journal of the National Cancer Institute, 2003, 95, 1586-1597.	6.3	140
128	The estrogen receptor: a model for molecular medicine. Clinical Cancer Research, 2003, 9, 1980-9.	7.0	317
129	Distinct molecular conformations of the estrogen receptor alpha complex exploited by environmental estrogens. Cancer Research, 2003, 63, 7490-6.	0.9	26
130	Structure-Function Relationships of the Raloxifene-Estrogen Receptor-Î± Complex for Regulating Transforming Growth Factor-Î± Expression in Breast Cancer Cells. Journal of Biological Chemistry, 2002, 277, 9189-9198.	3.4	68
131	Re: Effect of Long-Term Estrogen Deprivation on Apoptotic Responses of Breast Cancer Cells to 17beta-Estradiol and The Two Faces of Janus: Sex Steroids as Mediators of Both Cell Proliferation and Cell Death. Journal of the National Cancer Institute, 2002, 94, 1173-1173.	6.3	11
132	Effects of Raloxifene After Tamoxifen on Breast and Endometrial Tumor Growth in Athymic Mice. Journal of the National Cancer Institute, 2002, 94, 274-283.	6.3	65
133	Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo. Clinical Cancer Research, 2002, 8, 1995-2001.	7.0	25
134	Molecular Mechanism of Action at Estrogen Receptor Î± of a New Clinically Relevant Antiestrogen (GW7604) Related to Tamoxifen**This work was supported by NIH CA-56143 (to V.C.J.); Fundacì§ao Coordenacì§ao de Aperfeicì§oamento de Pessoal de Nìvel Superior, (CAPES) Scholarship, Brazil (to R.D.); the U.S. Army Medical Research and Material Command Breast Cancer Research Program, DAMD17â€“96-16169 (to H.L.); the generosity of the Lynn Sage Breast Cancer Research Foundation of Northwestern Memorial Hospital; and the. Endocrinology, 2001, 142, 838-846.	2.8	84
135	New strategies for the treatment of breast cancer. Breast Cancer, 2001, 8, 265-274.	2.9	0
136	Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial. Breast Cancer Research and Treatment, 2001, 65, 125-134.	2.5	629
137	Tamoxifen-Failed Male Breast Cancer with a High Level of Circulating Estrogen: Report of a Case. Surgery Today, 2001, 31, 149-151.	1.5	6
138	Chemoprevention with Antiestrogens: The Beginning of the End for Breast Cancer. Annals of the New York Academy of Sciences, 2001, 952, 60-72.	3.8	6
139	The Past, Present, and Future of Selective Estrogen Receptor Modulation. Annals of the New York Academy of Sciences, 2001, 949, 72-79.	3.8	47
140	Molecular Mechanism of Action at Estrogen Receptor Â of a New Clinically Relevant Antiestrogen (GW7604) Related to Tamoxifen. Endocrinology, 2001, 142, 838-846.	2.8	21
141	Surgical Oncology Forum: Tamoxifen for the Prevention of Breast Cancer in the High-Risk Woman. Annals of Surgical Oncology, 2000, 7, 67-71.	1.5	6
142	Tamoxifen: a personal retrospective. Lancet Oncology, The, 2000, 1, 43-49.	10.7	39
143	The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women. JAMA - Journal of the American Medical Association, 1999, 281, 2189.	7.4	1,661
144	Changes in lipid metabolism by tamoxifen. International Journal of Clinical Oncology, 1999, 4, 121-122.	2.2	0

#	Article	IF	Citations
145	Understanding the antiestrogenic actions of raloxifene and a mechanism of drug resistance to tamoxifen. Breast Cancer, 1998, 5, 99-106.	2.9	9
146	Laboratory models of breast and endometrial cancer to develop strategies for antiestrogen therapy. Breast Cancer, 1998, 5, 211-217.	2.9	5
147	Antiestrogenic Action of Raloxifene and Tamoxifen: Today and Tomorrow. Journal of the National Cancer Institute, 1998, 90, 967-971.	6.3	78
148	Questions about Tamoxifen and the Future Use of Antiestrogens. Oncologist, 1998, 3, 104-110.	3.7	13
149	Design of an ideal hormone replacement therapy for women. Molecular Carcinogenesis, 1996, 17, 108-111.	2.7	2
150	A Novel 80 kDa Human Estrogen Receptor Containing a Duplication of Exons 6 and 7. Nucleic Acids Research, 1996, 24, 962-969.	14.5	75
151	Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats. Breast Cancer Research and Treatment, 1994, 31, 11-25.	2.5	55
152	What do we know and what don't we know about tamoxifen in the human uterus. Breast Cancer Research and Treatment, 1994, 31, 27-39.	2.5	43
153	Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast Cancer Research and Treatment, 1994, 31, 117-127.	2.5	68
154	The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Research and Treatment, 1994, 31, 129-138.	2.5	144
155	The estrogenic activity of synthetic progestins used in oral contraceptives. Cancer, 1993, 71, 1501-1505.	4.1	49
156	An appraisal of strategies to reduce the incidence of breast cancer. Stem Cells, 1993, 11, 252-262.	3.2	14
157	A current view of tamoxifen for the treatment and prevention of breast cancer. British Journal of Pharmacology, 1993, 110, 507-517.	5.4	252
158	A Risk-Benefit Assessment of Tamoxifen Therapy. Drug Safety, 1993, 8, 381-397.	3.2	56
159	Investigation of the Mechanism of Tamoxifen-Stimulated Breast Tumor Growth With Nonisomerizable Analogues of Tamoxifen and Metabolites. Journal of the National Cancer Institute, 1993, 85, 806-812.	6.3	89
160	Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer. New England Journal of Medicine, 1992, 326, 852-856.	27.0	1,089
161	Growth Stimulation and Differential Regulation of Transforming Growth Factor-Î²1 (TGFÎ²1), TGFÎ²2, and TGFÎ²3 Messenger RNA Levels by Norethindrone in MCF-7 Human Breast Cancer Cells. Molecular Endocrinology, 1991, 5, 1120-1128.	3.7	57
162	Long-term adjuvant tamoxifen therapy for breast cancer. Breast Cancer Research and Treatment, 1990, 15, 125-136.	2.5	112

#	Article	IF	Citations
163	Preclinical studies with toremifene as an antitumor agent. Breast Cancer Research and Treatment, 1990, 16, S-S.	2.5	22
164	Toremifene as an Anticancer Agent. Cancer Investigation, 1990, 8, 271-272.	1.3	0
165	Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. European Journal of Cancer & Clinical Oncology, 1990, 26, 883-888.	0.7	107
166	Optimisation of antioestrogen therapy: laboratory and clinical concepts. Proceedings of the Royal Society of Edinburgh Section B Biological Sciences, 1989, 95, 239-246.	0.2	0
167	Regulation of Prolactin Synthesis in Vitro by Estrogenic and Antiestrogenic Derivatives of Estradiol and Estrone*. Endocrinology, 1989, 124, 1717-1726.	2.8	38
168	TAMOXIFEN AND ENDOMETRIAL CANCER. Lancet, The, 1989, 333, 733-734.	13.7	15
169	Short- and long-term estrogen deprivation of T47D human breast cancer cells in culture. European Journal of Cancer & Clinical Oncology, 1989, 25, 1777-1788.	0.7	43
170	Contrasting ability of antiestrogens to inhibit MCF-7 growth stimulated by estradiol or epidermal growth factor. European Journal of Cancer & Clinical Oncology, 1989, 25, 57-63.	0.7	62
171	The paracrine stimulation of MCF-7 cells by MDA-MB-231 cells: Possible role in antiestrogen failure. European Journal of Cancer & Clinical Oncology, 1989, 25, 493-497.	0.7	35
172	Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts. European Journal of Cancer & Clinical Oncology, 1989, 25, 1769-1776.	0.7	34
173	TAMOXIFEN AND ENDOMETRIAL CANCER. Lancet, The, 1988, 332, 1019.	13.7	27
174	Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model. European Journal of Cancer & Clinical Oncology, 1988, 24, 1817-1821.	0.7	47
175	Hormone Receptor Assays: Clinical Usefulness in the Management of Carcinoma of the Breast. CRC Critical Reviews in Clinical Laboratory Sciences, 1988, 26, 97-152.	1.0	54
176	Ligand Interaction at the Estrogen Receptor to Program Antiestrogen Action: A Study With Nonsteroidal Compoundsin Vitro*. Endocrinology, 1988, 122, 1449-1454.	2.8	48
177	Chemosuppression of Breast Cancer with Tamoxifen: Laboratory Evidence and Future Clinical Investigations. Cancer Investigation, 1988, 6, 589-595.	1.3	88
178	Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. European Journal of Cancer & Clinical Oncology, 1987, 23, 1935-1939.	0.7	110
179	Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Research and Treatment, 1987, 10, 31-35.	2.5	331
180	Long-term adjuvant tamoxifen study: Clinical update. Breast Cancer Research and Treatment, 1987, 9, 157-158.	2.5	37

#	Article	IF	Citations
181	Long-term tamoxifen adjuvant therapy in node-positive breast cancer: A metabolic and pilot clinical study. Breast Cancer Research and Treatment, 1984, 4, 297-302.	2.5	112
182	Binding of [3H] monohydroxytamoxifen in ovarian carcinoma. BJOG: an International Journal of Obstetrics and Gynaecology, 1983, 90, 751-758.	2.3	6
183	Interaction of [3H] estradiol â€" and [3H] monohydroxytamoxifen-estrogen receptor complexes with a monoclonal antibody. Breast Cancer Research and Treatment, 1983, 3, 267-277.	2.5	36
184	Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: Problems and potential for future clinical applications. Breast Cancer Research and Treatment, 1983, 3, S73-S86.	2.5	88
185	Inhibition of the Uterotropic Activity of Estrogens and Antiestrogens by the Short Acting Antiestrogen LY117018*. Endocrinology, 1983, 113, 463-468.	2.8	76
186	Binding of [3H]Monohydroxytamoxifen by Immature Rat Tissues in Vivo*. Endocrinology, 1982, 110, 1281-1291.	2.8	53